Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects

Lymphomas Clinical Trial

— DINAMIC  

Official title:

A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of RRx-001 in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Curative Therapies

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01359982
• Other study ID #: RRx001-11-01
• Status: Completed
• Phase: Phase 1
• First received: May 23, 2011
• Last updated: May 19, 2015
• Start date: September 2011
• Est. completion date: February 2015

Study information

• Verified date: May 2015
• Source: EpicentRx, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and pharmacokinetic profile of RRx-001 for injection in subjects with advanced solid tumors or lymphomas for which there are no currently accepted curative therapies. This study will also conduct an exploratory evaluation of objective tumor response using CT or MRI.

Description:

The DINAMIC (DINitroazetidines As Medications In Cancer) trial represents a provascular approach to temporarily change tumor blood flow and oxygenation. Blood supply to most tumors is poor, causing parts of tumors to have a low oxygen content which promotes aggressiveness and metastasis. The DINAMIC trial uses specific imaging techniques (including ultrasound), biopsy, and breath analysis to provide an early assessment of therapeutic activity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: February 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject is male or female, aged at least 18 years.

• Subject has a histologically or cytologically confirmed diagnosis of an advanced, malignant, incurable solid tumor(s) or lymphoma that is metastatic and/or unresectable and/or for which standard curative measures either are not applicable, or do not exist, or are no longer effective. Subjects with curative treatment options are not eligible for the protocol.

• Subject is not receiving any active treatment for his/her malignancy (except for prostate cancer subjects receiving luteinizing hormone-releasing hormone (LHRH) agonists and antiandrogens such as: Flutamide, Dutasteride, and Finasteride).

• Subject's Eastern Cooperative Group (ECOG) performance status is 0, 1 or 2 at Screening.

• Subject has acceptable liver function at Screening

• Subject has a normal serum creatinine.

• Subject has acceptable hematologic status at Screening

• Female subjects of childbearing potential (i.e., women who have not been surgically sterilized or have not been post-menopausal for at least one year), and male subjects with partners of childbearing potential, must agree to use medically acceptable methods of contraception beginning on Study Day 1 and continuing until at least four weeks after administration of the subject's final dose of RRx-001.

Exclusion Criteria:

• Impaired cardiac function that in the opinion of the Investigator could interfere with the conduct of the study or could put the subject at unacceptable risk.

• Right-to-left, bidirectional, or transient right-to-left cardiac shunts.

• Subjects with a history of acute cerebral infarction or transient ischemic attack within 90 days prior to Study Day 1.

• Acute myocardial infarction or acute coronary syndromes less than one year prior to enrollment.

• Serious ventricular arrythmias or high risk for arrhythmias due to prolongation of the QT interval.

• Subjects who experienced a major surgery, radiotherapy, or immunotherapy within the last 21 days prior to Study Day 1 (limited palliative radiation is allowed within 14 days prior to Study Day 1).

• Chemotherapy regimens with delayed toxicity within the 28 days prior to Study Day 1 (except for nitrosourea or mitomycin C treatments within 42 days prior to Study Day 1).

• Chemotherapy regimens given continuously or on a weekly basis that Investigator believes to have a limited potential for delayed toxicity within 14 days prior to Study Day 1.

• Use of an investigational anti-cancer drug within 42 days prior to Study Day 1.

• Subject has symptomatic and/or untreated central nervous system metastases and/or intracranial hypertension.

• Subject has a known history of an active and/or an uncontrolled infection with hepatitis A or hepatitis B.

• Subject with a known history of a positive HIV status.

• Subjects with pulmonary edema.

• Subjects with respiratory failure

• Subjects with severe emphysema, pulmonary emboli, pulmonary fibrosis or other conditions that cause pulmonary hypertension due to compromised pulmonary arterial vasculature.

• Subjects with Raynaud's syndrome.

• Subjects with a serious co-morbid medical condition.

• If female, subject is pregnant and/or breastfeeding.

• Any subject with congenital or acquired methemoglobinemia.

• Any subject with a history of inherited anemia or hemoglobinopathy including but not limited to hereditary spherocytosis, hereditary elliptocytosis, hereditary ovalocytosis,

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lymphomas
• Malignant Solid Tumor
• Neoplasms

Intervention

Drug:
• RRx-001
Dose level 1 (10 mg/m2)
• RRx-001
Dose Level 2 (16.7 mg/m2)
• RRx-001
Dose Level 3 (24.6 mg/m2)
• RRx-001
Dose Level 4 (33 mg/m2)
• RRx-001
Dose Level 5 (55.0 mg/m2)
• RRx-001
Dose Level 6 (83 mg/m2)

Locations

Country	Name	City	State
United States	Moores University of California San Diego Cancer Center	La Jolla	California
United States	Sarah Cannon Research Institute	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
EpicentRx, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number, frequency and type of adverse events		92 days	Yes